MCLEAN, Va., May 18, 2015 (GLOBE NEWSWIRE) -- Perthera, the premier personalized medicine service company, announced it will be hosting a breakfast panel and networking event for those in attendance of the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The meeting will be held Monday, June 1 from 6:30-7:30 a.m. in the Hyatt Regency McCormick Place, Grant Park D/CC12d.
To confirm your attendance for Beyond Genomics – A Multi-omic Systems Approach to Personalized Cancer Treatment1 attendees should register online at http://www.perthera.com/content/breakfast-roundtable-registration.
Leaders in the advancement of next-generation molecular diagnostics will connect to discuss how the use of personalized medicine is having an impact on clinical successes in the treatment of cancer. The incorporation of molecular diagnostic testing in practice is helping oncologists identify therapies that can be of significant benefit to their patients. The panel of experts will discuss:
- Obama's Precision Medicine Initiative
- The use of multiple, complementary diagnostics
- How molecular markers are guiding therapy selection
- Advances in the fight against pancreatic cancer
- The role of data science
- Emanuel F. Petricoin III, PhD
Co-Director, Center for Applied Proteomics and Molecular Medicine (CAPMM)
Professor, George Mason University
- Michael Pishvaian, MD, PhD
Director of the Phase I Clinical Trial Program, Lombardi Comprehensive Cancer Center
Assistant Professor in Hematology/Oncology, Georgetown University Medical Center
- Subha Madhavan, PhD
Director, Innovation Center for Biomedical Informatics (ICBI)
Associate Professor of Oncology, Georgetown University Medical Center
In addition to serving as host for the networking breakfast panel, Perthera will exhibiting in booth #6028, where executives will meet with attendees interested in learning more about the increasing importance of personalized medicine in today's treatment of cancer.
Perthera, based in McLean, Va, is the premier personalized medicine service company. As the only organization to combine the latest multi-omic molecular profiling, including genomic, proteomic and phosphoproteomic analysis, with a patient's medical history and state-of-the-art diagnostic technology, Perthera enables oncologists to deliver precision medicine to treat an individual patient's unique cancer. For more information, visit us on www.perthera.com, Twitter, Facebook and YouTube.
1Not an official event of the 2015 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or The Conquer Cancer Foundation.
CONTACT: Press contacts Dave Anderson, on behalf of Perthera 678-401-2991 email@example.com